FDA's new safety controls for LABA-containing drugs will impact prescribing for the treatment of asthma
Some US physicians have indicated that they will decrease their overall prescribing of long-acting beta2 agonists (LABA)/inhaled corticosteroids (ICS) combination therapies over the next 12 months for the treatment of asthma in response to the US Food and Drug Administration's new safety controls for LABA-containing medications (The Pharma Letter June 3).
Most notably, the FDA controls state that LABA/ICS combination medications should be reserved for patients who remain uncontrolled despite treatment with controller medications (eg, single-agent ICS therapies).
According to the new report titled Treatment Algorithms in Asthma, from advisory firm Decision Resources, more than 40% of surveyed physicians report that they will decrease their prescribing of LABA/ICS combinations prior to attempting treatment with a single-agent ICS drug over the next 12 months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze